BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 22987267)

  • 1. Impact of liposomal amphotericin B on renal function in critically ill patients with renal function impairment.
    Alvarez-Lerma F; Soriano MC; Rodríguez M; Catalán M; Llorente AM; Vidart N; Garitacelaya M; Maraví E; Fernández E; Alvarado F; López M; Alvarez-Sánchez B; Espinosa J; Quintana E;
    Rev Esp Quimioter; 2012 Sep; 25(3):206-15. PubMed ID: 22987267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of liposomal amphotericin B in patients admitted to the ICU on renal replacement therapy.
    Álvarez-Lerma F; Rodriguez M; Soriano MC; Catalán M; Llorente AM; Vidart N; Garitacelaya M; Maravi E; Fernández Rey E; Alvarado F; López-Sánchez M; Alvarez-Sánchez B; Granado D; Quintana E;
    Rev Esp Quimioter; 2013 Dec; 26(4):360-8. PubMed ID: 24399350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liposomal amphotericin B does not induce nephrotoxicity or renal function impairment in premature neonates.
    Manzoni P; Galletto P; Rizzollo S; Franco C; Gallo E; Antonucci R; Fanos V; Farina D
    Early Hum Dev; 2012 May; 88 Suppl 2():S86-91. PubMed ID: 22633524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Impact on renal function of an early switch from conventional to liposomal amphotericin B formulation in the empirical treatment of fungal infections].
    Isnard F; Tilleul P; Laporte JP; Chevallier P; Pigneux A; Lafuma A; Monchecourt F; Mahi L; Deray G
    Med Mal Infect; 2008 Apr; 38(4):208-14. PubMed ID: 18191521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Liposomal amphotericin B in the treatment of severe fungal infections. Results of a clinical cohort trial].
    Rieger CT; Dittmer M; Ostermann H
    Dtsch Med Wochenschr; 2007 Oct; 132(40):2062-6. PubMed ID: 17899499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Institutional experience with voriconazole compared with liposomal amphotericin B as empiric therapy for febrile neutropenia.
    Shehab N; DePestel DD; Mackler ER; Collins CD; Welch K; Erba HP
    Pharmacotherapy; 2007 Jul; 27(7):970-9. PubMed ID: 17594202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Retrospective investigation on the cases treated with liposomal amphotericin B].
    Yamagishi Y; Mikamo H
    Jpn J Antibiot; 2010 Oct; 63(5):347-64. PubMed ID: 21268407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The evaluation of frequency of nephrotoxicity caused by liposomal amphotericin B.
    Kato H; Hagihara M; Yamagishi Y; Shibata Y; Kato Y; Furui T; Watanabe H; Asai N; Koizumi Y; Mikamo H
    J Infect Chemother; 2018 Sep; 24(9):725-728. PubMed ID: 29773439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Occurrence and improvement of renal dysfunction and serum potassium abnormality during administration of liposomal amphotericin B in patients with hematological disorders: A retrospective analysis.
    Yamazaki H; Kondo T; Aoki K; Yamashita K; Takaori-Kondo A
    Diagn Microbiol Infect Dis; 2018 Feb; 90(2):123-131. PubMed ID: 29203252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amphotericin B deoxycholate (d-AMB) use in cases with febrile neutropenia and fungal infections: lower toxicity with suitable premedication.
    Oto OA; Paydas S; Disel U; Yavuz S; Seydaoglu G
    Mycoses; 2007 Mar; 50(2):135-9. PubMed ID: 17305778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome.
    Mattiuzzi GN; Estey E; Raad I; Giles F; Cortes J; Shen Y; Kontoyiannis D; Koller C; Munsell M; Beran M; Kantarjian H
    Cancer; 2003 Jan; 97(2):450-6. PubMed ID: 12518369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study of renal safety in amphotericin B lipid complex-treated patients.
    Alexander BD; Wingard JR
    Clin Infect Dis; 2005 May; 40 Suppl 6():S414-21. PubMed ID: 15809928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group.
    Walsh TJ; Finberg RW; Arndt C; Hiemenz J; Schwartz C; Bodensteiner D; Pappas P; Seibel N; Greenberg RN; Dummer S; Schuster M; Holcenberg JS
    N Engl J Med; 1999 Mar; 340(10):764-71. PubMed ID: 10072411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countries.
    Ullmann AJ; Sanz MA; Tramarin A; Barnes RA; Wu W; Gerlach BA; Krobot KJ; Gerth WC;
    Clin Infect Dis; 2006 Aug; 43(4):e29-38. PubMed ID: 16838223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuous and 4 h infusion of amphotericin B: a comparative study involving high-risk haematology patients.
    Peleg AY; Woods ML
    J Antimicrob Chemother; 2004 Oct; 54(4):803-8. PubMed ID: 15308606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of liposomal amphotericin B versus an amphotericin B lipid complex on liver histopathology in patients with hematologic malignancies and invasive fungal infections: a retrospective, nonrandomized autopsy study.
    Chamilos G; Luna M; Lewis RE; Chemaly R; Raad II; Kontoyiannis DP
    Clin Ther; 2007 Sep; 29(9):1980-6. PubMed ID: 18035197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nephrotoxicity and other adverse events among inpatients receiving liposomal amphotericin B or amphotericin B lipid complex.
    Wade RL; Chaudhari P; Natoli JL; Taylor RJ; Nathanson BH; Horn DL
    Diagn Microbiol Infect Dis; 2013 Jul; 76(3):361-7. PubMed ID: 23774005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors of amphotericin B toxicty in the nonneonatal pediatric population.
    Dutta A; Palazzi DL
    Pediatr Infect Dis J; 2012 Sep; 31(9):910-4. PubMed ID: 22581225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of nephrotoxicity in patients receiving amphotericin B lipid complex: a pharmacosurveillance study in Spain.
    Aguado JM; Lumbreras C; González-Vidal D;
    Clin Microbiol Infect; 2004 Sep; 10(9):785-90. PubMed ID: 15355408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipid formulations of amphotericin B preserve and stabilize renal function in HSCT recipients.
    Miller CB; Waller EK; Klingemann HG; Dignani MC; Anaissie EJ; Cagnoni PJ; McSweeney P; Fleck PR; Fruchtman SM; McGuirk J; Chao NJ
    Bone Marrow Transplant; 2004 Mar; 33(5):543-8. PubMed ID: 14730342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.